Avet-logo (Avet Logo)
Leflunomide Tablet
Product Images NDC 71335-2874
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 71335-2874). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure-1 (Figure 1)
Bar chart showing the percentage of ACR 20 responders at the endpoint across three clinical trials of different durations (12 months, 6 months, 12 months). It compares response rates for leflunomide (L), methotrexate (M), placebo (P), and sulfasalazine (S) with values ranging from below 0% to about 60%.*
Figure-2 (Figure 2)
A line graph titled 'Trial 1 ACR Responders Over Time' showing the percentage of responders over a 12-month period. The x-axis represents time in months (0 to 12), and the y-axis shows percentage responders (from -10% to 70%). The graph includes three data series labeled PL (placebo), MTX (methotrexate), and LEF (leflunomide), each represented by distinct markers and lines. LEF shows the highest responder percentage across the timeline. The note indicates 'Last Observation Carried Forward.'*
Figure-3 (Figure 3)
A bar chart titled "Change in Sharp Score" showing disease progression over three clinical trials of varying lengths (6 to 12 months). The x-axis categorizes different treatments labeled L (leflunomide), M (methotrexate), S (sulfasalazine), and P (placebo). The y-axis measures progression from -10 to 8. Numeric values accompany each bar.*
Figure-4 (Figure 4)
A bar chart titled 'Change in Functional Ability Measure' showing improvement measured by the HAQ Disability Index across three trials of different durations. The chart compares Leflunomide (L), Methotrexate (M), Placebo (P), and Sulfasalazine (S) with bars representing changes in functional ability, indicating numerical improvement values below zero on the y-axis.*
Label (Lbl713352874)
Label for Leflunomide Tablets, USP 10 mg by Bryant Ranch Prepack. The label indicates the product contains 30 tablets and includes storage instructions to keep at 25°C with permitted excursions between 15° and 30°C, protect from light, and a warning to keep out of reach of children. The product is manufactured by Heritage Pharma Labs Inc. Barcodes and QR codes for prescribing information and package insert are also shown.*
Structural-formula (Structural Formula)
Chemical structure of leflunomide depicting its molecular arrangement including functional groups such as an isoxazole ring and a trifluoromethyl-substituted phenyl ring connected by a carbamate linkage.*
Teriflunomide-structural-formula. (Teriflunomide Structural Formula)
Chemical structure of the active ingredient teriflunomide, associated with leflunomide. The diagram depicts the molecular structure with labeled bonds and functional groups.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
